A Smart Tufts CEVR Look at Every Cost-Effectiveness Analysis Published for the Meds CMS Is Currently ‘Negotiating’
Shares:
It’s the New Year. It’s a time to refresh and reflect and reconnect. In that spirit, I have two asks of you: First: If you find the newsletter useful, please
Yesterday, we saw three blowouts and one nail-biter. The details are below, but if you’re caffeinated and must rush, here’s today’s ballot. I’m not particularly surprised that “IRA’s 10 selected
The Wall Street Journal covered, with some depth, the trend of biosimilars launching with two prices: a low price designed to be appealing to consumers (and, I guess, media) and